Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)

Inclusion Criteria: 1. Participants must be \>18 years of age at the time of randomization 2. Acute non-cardioembolic ischemic stroke in the anterior circulation treated with reperfusion therapy defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) 3. Time from end of acute reperfusion therapy to randomization ≤ 24 hours 4. Mild to moderate deficit defined as a National Institute of Health stroke scale of ≤11 at the time of randomization 5. At least one non-contrast CT scan completed post reperfusion therapy and prior to randomization without any hemorrhage (including hemorrhagic infarction) and/or contrast extravasation. 6. Premorbid mRS less than or equal to 2 7. Signed informed consent from the patient or legally authorized representative Exclusion Criteria: 1. Any known disorder associated with a significantly increased risk of bleeding 2. Post-reperfusion CT scan ASPECT score \<8. 3. Anticoagulation is required for any indication other than DVT prophylaxis 4. Evidence-based indication for dual antiplatelet therapy 5. Planned surgical intervention in the next 90 days includes but is not limited to carotid endarterectomy, where dual antiplatelet is not indicated, and carotid stenting, where single antiplatelet is not used. 6. History of intracranial or subarachnoid hemorrhage 7. Intracranial tumour, arteriovenous malformation or aneurysm; 8. Intracranial or spinal cord surgery within three months; 9. Gastrointestinal or urinary tract hemorrhage within the previous 21 days; 10. Coagulation disorder, thrombocytopenia \<100, 000/mm3, and Prothrombin time INR ≥1.8 11. Index stroke is caused by infective endocarditis, dissection, systematic or central nervous system vasculitis 12. History of active malignancy being treated or life expectancy ≤ 90 days 13. Allergy to clopidogrel or aspirin 14. Pregnancy 15. Participation in another clinical trial. 16. The presence of a major co-morbid illness that would make it unlikely that the participant will be able to complete follow-up